Bridget Mc Kay
About Bridget Mc Kay
Bridget McKay is a Research Associate at Mammoth Biosciences, with a background in molecular biology and biochemistry. She has previously worked at Telomere Diagnostics and Stanford University School of Medicine, and holds a Bachelor of Applied Science from the University of Arizona College of Medicine.
Work at Mammoth Biosciences
Bridget Mc Kay has been employed as a Research Associate at Mammoth Biosciences since 2019. Located in South San Francisco, California, her role involves conducting research and development activities related to CRISPR technology. She has contributed to the advancement of molecular biology techniques within the organization, focusing on the testing and characterization of CRISPR proteins.
Previous Experience at Telomere Diagnostics, Inc.
Prior to her current position, Bridget Mc Kay worked as a Research and Development Intern at Telomere Diagnostics, Inc. in Menlo Park, California, for four months in 2018. During this internship, she gained practical experience in the field of molecular diagnostics, enhancing her skills in research methodologies.
Experience at Stanford University School of Medicine
Bridget Mc Kay served as a Research Associate at Stanford University School of Medicine from 2018 to 2019. Her tenure lasted for 11 months, during which she engaged in various research projects that contributed to the scientific community's understanding of medical research.
Education and Expertise
Bridget Mc Kay studied at the University of Arizona College of Medicine – Tucson from 2012 to 2017, where she earned a Bachelor of Applied Science and a Bachelor of Science. Her educational background provided her with a solid foundation in medicine and biological sciences. She possesses expertise in standard biochemical and molecular biology techniques, including PCR, Western blotting, and cloning methods.
Research Skills and Techniques
Bridget Mc Kay has developed sensitive and robust Standard Operating Procedures (SOPs) to support the testing and characterization of CRISPR proteins in vivo. She is proficient in RNA synthesis, including sequence optimization for stability and translation, and the incorporation of modified nucleotides. Additionally, she has experience with high-throughput screening (HTS) and the analysis of new CRISPR systems.